Vanguard Group’s Marker Therapeutics MRKR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $516K | Buy |
346,074
+46,293
| +15% | +$52.4K | ﹤0.01% | 3938 |
|
|
2025
Q3 | $268K | Buy |
299,781
+24,436
| +9% | +$30.2K | ﹤0.01% | 4075 |
|
|
2025
Q2 | $421K | Hold |
275,345
| – | – | ﹤0.01% | 3959 |
|
|
2025
Q1 | $339K | Buy |
275,345
+32,223
| +13% | +$59K | ﹤0.01% | 3971 |
|
|
2024
Q4 | $756K | Hold |
243,122
| – | – | ﹤0.01% | 3838 |
|
|
2024
Q3 | $686K | Buy |
243,122
+4,800
| +2% | +$19K | ﹤0.01% | 3890 |
|
|
2024
Q2 | $1.29M | Buy |
238,322
+5,091
| +2% | +$21.6K | ﹤0.01% | 3707 |
|
|
2024
Q1 | $1M | Buy |
233,231
+8,174
| +4% | +$35.7K | ﹤0.01% | 3811 |
|
|
2023
Q4 | $1.24M | Buy |
225,057
+3,975
| +2% | +$13.5K | ﹤0.01% | 3759 |
|
|
2023
Q3 | $1M | Buy |
221,082
+55,483
| +34% | +$310K | ﹤0.01% | 3826 |
|
|
2023
Q2 | $513K | Sell |
165,599
-1,282
| -0.8% | -$2.23K | ﹤0.01% | 4114 |
|
|
2023
Q1 | $118K | Sell |
166,881
-9,904
| -6% | -$23.5K | ﹤0.01% | 4387 |
|
|
2022
Q4 | $470K | Buy |
176,785
+156
| +0.1% | +$538 | ﹤0.01% | 4114 |
|
|
2022
Q3 | $651K | Sell |
176,629
-54,100
| -23% | -$199K | ﹤0.01% | 4147 |
|
|
2022
Q2 | $761K | Hold |
230,729
| – | – | ﹤0.01% | 4174 |
|
|
2022
Q1 | $1.01M | Sell |
230,729
-38,078
| -14% | -$218K | ﹤0.01% | 4204 |
|
|
2021
Q4 | $2.55M | Sell |
268,807
-364
| -0.1% | -$4.83K | ﹤0.01% | 3952 |
|
|
2021
Q3 | $4.55M | Hold |
269,171
| – | – | ﹤0.01% | 3723 |
|
|
2021
Q2 | $7.51M | Buy |
269,171
+14,222
| +6% | +$374K | ﹤0.01% | 3365 |
|
|
2021
Q1 | $5.71M | Buy |
254,949
+115,730
| +83% | +$2.65M | ﹤0.01% | 3459 |
|
|
2020
Q4 | $2.02M | Sell |
139,219
-6,518
| -4% | -$101K | ﹤0.01% | 3656 |
|
|
2020
Q3 | $2.19M | Sell |
145,737
-7,615
| -5% | -$139K | ﹤0.01% | 3458 |
|
|
2020
Q2 | $3.17M | Sell |
153,352
-801
| -0.5% | -$17.5K | ﹤0.01% | 3288 |
|
|
2020
Q1 | $2.93M | Sell |
154,153
-528
| -0.3% | -$13.5K | ﹤0.01% | 3188 |
|
|
2019
Q4 | $4.46M | Sell |
154,681
-581
| -0.4% | -$21.1K | ﹤0.01% | 3208 |
|
|
2019
Q3 | $7.93M | Buy |
155,262
+12,875
| +9% | +$761K | ﹤0.01% | 2934 |
|
|
2019
Q2 | $11.3M | Buy |
142,387
+19,847
| +16% | +$1.18M | ﹤0.01% | 2791 |
|
|
2019
Q1 | $8.09M | Buy |
122,540
+27,016
| +28% | +$1.58M | ﹤0.01% | 2936 |
|
|
2018
Q4 | $5.3M | Buy |
95,524
+57,933
| +154% | +$4.22M | ﹤0.01% | 3067 |
|
|
2018
Q3 | $3.4M | Buy |
37,591
+18,821
| +100% | +$1.62M | ﹤0.01% | 3361 |
|
|
2018
Q2 | $1.77M | Buy |
18,770
+5,080
| +37% | +$259K | ﹤0.01% | 3538 |
|
|
2018
Q1 | $455K | Buy |
13,690
+4,655
| +52% | +$164K | ﹤0.01% | 3804 |
|
|
2017
Q4 | $356K | Buy |
9,035
+850
| +10% | +$26.1K | ﹤0.01% | 3824 |
|
|
2017
Q3 | $246K | Buy |
+8,185
| New | +$258K | ﹤0.01% | 3878 |
|
Other funds holding MRKR
NMC
BOCH
ACM
NA
Vanguard Group's MRKR Position: Q4 2025 in Review
Vanguard Group increased its Marker Therapeutics (MRKR) stake by 15% in Q4 2025, buying an estimated $52.4K and bringing the position to 346,074 shares worth $516K. The position accounts for ﹤0.01% of the portfolio, ranked #3938.
Vanguard Group first reported a position in MRKR in Q3 2017 and has held it in 34 quarters since. The position peaked at $11.3M in Q2 2019. 36 funds tracked by Wall St. Rank hold MRKR as of Q4 2025.
- Vanguard Group held 346,074 shares of Marker Therapeutics worth $516K as of Q4 2025.
- Vanguard Group bought 46,293 Marker Therapeutics shares in Q4 2025, an estimated $52.4K.
- Marker Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3938 holding.
- Vanguard Group first reported a position in Marker Therapeutics in Q3 2017 and has held it in 34 quarters since.
- Vanguard Group's Marker Therapeutics position peaked at $11.3M in Q2 2019.
- 36 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.